Humanigen (OTCPK:HGEN.Q) - Aandelenkoers, Nieuws & Analyse

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

HGEN.Q Overzicht aandelen

A clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. Meer informatie

HGEN.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

De omzet is het afgelopen jaar met 59% gedaald

Heeft geen betekenisvolle marktkapitalisatie ( $119 )

Negatief eigen vermogen

+ 2 meer risico's

Humanigen, Inc. Concurrenten

ObsEva

OTCPK:OBSE.F

US$11.7k

Mymetics

OTCPK:MYMX

US$151.0

Infinity Pharmaceuticals

OTCPK:INFI.Q

US$90.0

RegeneRx Biopharmaceuticals

OTCPK:RGRX

US$2.1k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Humanigen
Historische aandelenkoersen
Huidige aandelenkoers	US$0.000001
52 Week Hoogtepunt	US$0.21
52 Week Laag	US$0.000001
Bèta	-1.34
11 maand verandering	0%
3 maanden verandering	0%
1 Jaar Verandering	-100.00%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

Rendement voor aandeelhouders

	HGEN.Q	US Biotechs	US Markt
7D	-99.5%	2.5%	2.2%
1Y	-100.0%	16.1%	31.6%

Rendement versus industrie: HGEN.Q presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.1 % opleverde.

Rendement versus markt: HGEN.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is HGEN.Q's price volatile compared to industry and market?
HGEN.Q volatility
HGEN.Q Average Weekly Movement	102,515.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van HGEN.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van HGEN.Q is het afgelopen jaar gestegen van 50618% naar 102515%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	6	Cameron Durrant	www.humanigen.com

Humanigen, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Humanigen zich tot de beurswaarde?
HGEN.Q fundamentele statistieken
Marktkapitalisatie	US$119.00
Inkomsten(TTM)	-US$53.63m
Inkomsten(TTM)	US$1.70m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is HGEN.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HGEN.Q resultatenrekening (TTM)
Inkomsten	US$1.70m
Kosten van inkomsten	US$38.73m
Brutowinst	-US$37.03m
Overige uitgaven	US$16.61m
Inkomsten	-US$53.63m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.45
Brutomarge	-2,179.40%
Nettowinstmarge	-3,156.80%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde HGEN.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

This company is no longer active

HGEN.Q Overzicht aandelen

Risicoanalyse

Humanigen, Inc. Concurrenten

OTCPK:OBSE.F

US$11.7k

OTCPK:MYMX

US$151.0

OTCPK:INFI.Q

US$90.0

OTCPK:RGRX

US$2.1k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Humanigen, Inc. Filed for Bankruptcy

Levi & Korsinsky, LLP and Pomerantz LLP Announce A Proposed Settlement for the in Re Humanigen, Inc. Securities Litigation

The Nasdaq Stock Market to Delist the Common Stock of Humanigen

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index

Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index

Recent updates

Humanigen, Inc. Filed for Bankruptcy

Levi & Korsinsky, LLP and Pomerantz LLP Announce A Proposed Settlement for the in Re Humanigen, Inc. Securities Litigation

The Nasdaq Stock Market to Delist the Common Stock of Humanigen

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index

Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index

Humanigen, Inc. Announces Board Changes

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.035 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.75

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Humanigen Receives Non-Compliance Letter from Nasdaq

Bernstein Liebhard LLP Announces Class Action Lawsuit Against Humanigen, Inc

Humanigen, Inc. Announces Executive Changes

Humanigen, Inc. Announces Resignation Adrian Kilcoyne as Chief Medical Officer, Effective September 28, 2022

Pomerantz LLP Announces the Filing of a Class Action Against Humanigen, Inc. and Certain of its Officers

Consensus revenue estimates increase by 34%

First half 2022 earnings released

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Price target decreased to US$8.70

Humanigen, Inc. Receives Preliminary Topline Data from NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

Humanigen plunges 57% as trial for COVID-19 therapy fails

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Consensus revenue estimates increase by 19%

Humanigen, Inc., Annual General Meeting, Jun 09, 2022

Chairman & CEO recently bought US$94k worth of stock

Forecast to breakeven in 2023

Consensus revenue estimates increase by 12%

Forecast to breakeven in 2023

Humanigen Launches Managed Access Program for Lenzilumab

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

Humanigen, Inc. Announces Target Enrollment in Phase 2/3 Activ-5/Bet-B Trial of Lenzilumab for the Treatment of Covid-19 Has Been Achieved

Humanigen, Inc. Announces A Manuscript Detailing the Results of an Analysis of CRP Levels from the Live-Air Phase 3 Study

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

FDA Declines Humanigen’s Emergency Use Authorization Request for Lenzilumab in Hospitalized COVID-19 Patients

Price target decreased to US$28.33

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Chairman & CEO recently sold US$1.7m worth of stock

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Humanigen Submits Application to FDA for Emergency Use Authorization for lenzilumab in Covid-19

Humanigen submits lenzilumab COVID-19 EUA application to FDA

Eversana Advances Commercialization Readiness as Humanigen Announces Publication of Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Newly Hospitalized Covid-19 Patients

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Price target increased to US$32.14

Humanigen, Inc., Annual General Meeting, Jun 17, 2021

Humanigen, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Earnings beat expectations

Chief Accounting & Administrative Officer, Corporate Secretary and Treasurer has left the company

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

New 90-day high: US$23.83

Humanigen, Inc. Announces Executive Changes

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing